The majority of patients treated with immunotherapy as a standalone therapy experience little to no benefits.
Tubulin tyrosine ligase 12 (TTLL12), as a member of the tubulin tyrosine ligase protein family, is associated with the prognosis of patients with cancer and implicated in regulating innate immunity.
However, the role of TTLL12 in modulating antitumor immunity remains unclear.
